Acute Liver Failure Secondary to Remdesivir in the Treatment of COVID-19

Remdesivir has been the mainstay of coronavirus disease 2019 treatment since the start of the severe acute respiratory syndrome coronavirus 2 pandemic. Despite its growing use, safety data are limited. We present the case of an elderly man with obesity and coronavirus disease 2019 who developed acut...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Kevin, Gausman, Valerie, Poles, Michael, Popov, Violeta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9534366/
https://www.ncbi.nlm.nih.gov/pubmed/36212242
http://dx.doi.org/10.14309/crj.0000000000000866
_version_ 1784802525635936256
author Lin, Kevin
Gausman, Valerie
Poles, Michael
Popov, Violeta
author_facet Lin, Kevin
Gausman, Valerie
Poles, Michael
Popov, Violeta
author_sort Lin, Kevin
collection PubMed
description Remdesivir has been the mainstay of coronavirus disease 2019 treatment since the start of the severe acute respiratory syndrome coronavirus 2 pandemic. Despite its growing use, safety data are limited. We present the case of an elderly man with obesity and coronavirus disease 2019 who developed acute liver failure after initiation of remdesivir. This report broadens our knowledge of the side effect profile of remdesivir and discusses potential risk factors and an approach to remdesivir-induced liver failure. Our case also highlights the importance of monitoring hepatic function after initiation of therapy with remdesivir.
format Online
Article
Text
id pubmed-9534366
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wolters Kluwer
record_format MEDLINE/PubMed
spelling pubmed-95343662022-10-07 Acute Liver Failure Secondary to Remdesivir in the Treatment of COVID-19 Lin, Kevin Gausman, Valerie Poles, Michael Popov, Violeta ACG Case Rep J Case Report Remdesivir has been the mainstay of coronavirus disease 2019 treatment since the start of the severe acute respiratory syndrome coronavirus 2 pandemic. Despite its growing use, safety data are limited. We present the case of an elderly man with obesity and coronavirus disease 2019 who developed acute liver failure after initiation of remdesivir. This report broadens our knowledge of the side effect profile of remdesivir and discusses potential risk factors and an approach to remdesivir-induced liver failure. Our case also highlights the importance of monitoring hepatic function after initiation of therapy with remdesivir. Wolters Kluwer 2022-10-06 /pmc/articles/PMC9534366/ /pubmed/36212242 http://dx.doi.org/10.14309/crj.0000000000000866 Text en © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Case Report
Lin, Kevin
Gausman, Valerie
Poles, Michael
Popov, Violeta
Acute Liver Failure Secondary to Remdesivir in the Treatment of COVID-19
title Acute Liver Failure Secondary to Remdesivir in the Treatment of COVID-19
title_full Acute Liver Failure Secondary to Remdesivir in the Treatment of COVID-19
title_fullStr Acute Liver Failure Secondary to Remdesivir in the Treatment of COVID-19
title_full_unstemmed Acute Liver Failure Secondary to Remdesivir in the Treatment of COVID-19
title_short Acute Liver Failure Secondary to Remdesivir in the Treatment of COVID-19
title_sort acute liver failure secondary to remdesivir in the treatment of covid-19
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9534366/
https://www.ncbi.nlm.nih.gov/pubmed/36212242
http://dx.doi.org/10.14309/crj.0000000000000866
work_keys_str_mv AT linkevin acuteliverfailuresecondarytoremdesivirinthetreatmentofcovid19
AT gausmanvalerie acuteliverfailuresecondarytoremdesivirinthetreatmentofcovid19
AT polesmichael acuteliverfailuresecondarytoremdesivirinthetreatmentofcovid19
AT popovvioleta acuteliverfailuresecondarytoremdesivirinthetreatmentofcovid19

Ejemplares similares